Drug Device Combination products Market Primed to Grow due to Rising Prevalence of Chronic Diseases
Drug Device Combination products Market |
The combination drug device market has been witnessing significant growth due to the rising prevalence of chronic diseases leading to increased demand for combination products that provide efficacy and convenience. Combination drug devices offer advantages such as enhanced drug delivery, improved patient compliance and synchronization of drugs with devices leading to better therapeutic outcomes.
The
Global Drug Device Combination Products Market is estimated to be valued at US$
173.07 Mn in 2024 and is expected to exhibit a CAGR of 3.7% over the forecast
period 2024 to 2030.
Key Takeaways
Key players operating in the combination drug device market are Evonik
Industries AG (RAG-Stiftung), JSR Corporation, Kumho Petrochemical Co. Ltd.,
Kuraray Co. Ltd., Lanxess AG, Nippon Soda Co. Ltd., Reliance Industries
Limited, Saudi Basic Industries Corporation (Aramco Chemicals Company),
Synthomer PLC, Synthos (Ftf Galleon S.A.), UBE Corporation, Versalis (Eni
S.p.A.). Some of the major opportunities in the market include development of
combination products for respiratory diseases, diabetes, auto-immune disorders
and oncology. Globally, the market is expected to witness high growth in Asia
Pacific region owing to rising healthcare expenditure, large patient pool and
increasing focus of players to tap opportunities in the emerging countries.
Key opportunities in the combination drug device market include development of
products with enhanced polymer drug delivery technologies for drugs having
short half-lives, focus on devices for sustained drug delivery especially for
chronic diseases like diabetes, collaborations of drug developers with device
companies for development of innovative combination products. The combination
drug device market is expected to witness robust growth in Asia Pacific region
majorly driven by rise in chronic disease prevalence, increasing focus of major
players to expand presence in countries like China, India, South Korea and rise
in healthcare spending in the region.
Market drivers: The rising prevalence of chronic diseases is a major growth
driver for combination drug device market. According to WHO, chronic diseases
account for over 60% of total deaths globally. Increased spending on healthcare
fueled by rising disposable incomes is also supporting the market growth.
Regulatory policies favoring development of innovative combination products
along with availability of polymer-based drug delivery technologies will
continue to boost the demand in coming years.
PEST Analysis
Political: Regulations around the development and approval of Global
Drug Device Combination Products Market Size are complex given the involvement of
regulatory agencies like the US FDA. Any changes in regulations can impact the
development timeline and market approvals.
Economic: The industry is dependent on healthcare spending of both government
and private insurance companies. Economic slowdowns can negatively impact the
spending on specialty drug device products due to their high prices.
Social: An aging global population and growing incidence of chronic diseases
like diabetes and cardiovascular conditions are increasing the demand for
convenient drug delivery methods like drug device combinations. However, social
acceptance of newer application modes need to be established.
Technological: Continuous innovation is happening in drug delivery technologies
ranging from patches to injectables to implantables. Integration of drugs and
devices as combinations opens new possibilities for sustained and targeted
delivery but requires extensive R&D investments.
The geographical regions where the drug device combination products market is
concentrated in terms of value currently are North America and Europe. This is
because of the advanced healthcare infrastructure and spending in countries
like the US, Canada, Germany, France and the UK which are early adopters of
innovative medical technologies. However, Asian markets like China and India
are emerging as the fastest growing regions due to their large patient
populations, increasing income levels, and focus of industry players on these
regions. Governments in Asian countries are also supportive through initiatives
to improve access to healthcare.
India has a distinct advantage due to its large generic drugs industry and
developing capabilities in medical technologies. Local companies are partnering
with global pharma innovators to introduce affordable drug device combinations
catering to diseases prevalent in the country. The Indian government's 'Make in
India' campaign is also encouraging local manufacturing of such specialty
products to not just meet domestic needs butAlso, for exports. This is
attracting significant investments into R&D and manufacturing facilities in
India making it one of the fastest growing sectors and regions in this market
over the forecast period.
Get
more insights on- Drug
Device Combination Products Market
Check
more trending articles related to this topic: secondary
batteries market
Comments
Post a Comment